Dr. Geoffrey A. Block, M.D. is Independent Director of the Company. Dr. Block has served as the Associate Chief Medical Officer of U.S. Renal Care since February 2020. Prior to that, Dr. Block served as Vice President, Nephrology of Reata Pharmaceuticals, Inc. (Nasdaq: RETA) from January 2019 to January 2020. Prior to that, Dr. Block held a variety of positions with the Denver Nephrology Division at Colorado Kidney Care/Denver Nephrologists, most recently serving as the Director of Clinical Research from 1998 to 2018. Dr. Block served as an associate professor in medicine at the University of Colorado Health Sciences Center from 2008 to 2018. Prior to that, Dr. Block served as an attending physician at St. Joseph’s Hospital and as the medical director of the DaVita-Lowry Hemodialysis Unit. Dr. Block received his M.D. from the University of Cincinnati College of Medicine and completed his fellowship in nephrology at that the University of Michigan at Ann Arbor. Block is qualified to serve on our board of directors due to his extensive experience in the field of nephrology, and his unique ability to understand the treatment options, needs and challenges for the patients we expect to serve.
As the Independent Director of Ardelyx Inc, the total compensation of Geoffrey Block at Ardelyx Inc is $230,508. There are 6 executives at Ardelyx Inc getting paid more, with Michael Raab having the highest compensation of $1,728,920.
Geoffrey Block is 54, he's been the Independent Director of Ardelyx Inc since 2019. There are 14 older and 4 younger executives at Ardelyx Inc. The oldest executive at Ardelyx Inc is Gordon Ringold, 69, who is the Independent Director.
Geoffrey's mailing address filed with the SEC is C/O ARDELYX, INC., 400 FIFTH AVENUE, SUITE 210, WALTHAM, MA, 02451.
Over the last 10 years, insiders at Ardelyx Inc have traded over $37,312,621 worth of Ardelyx Inc stock and bought 85,247,838 units worth $820,614,871 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Ardelyx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $1,784,764. The most recent stock trade was executed by Michael Raab on 27 August 2024, trading 7,500 units of ARDX stock currently worth $46,650.
ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.
Ardelyx Inc executives and other stock owners filed with the SEC include: